The Latest
-
iStock via Getty Images
A myriad of blows: Who's getting hit the hardest by the economy's troubles
The downturn shows few signs of hurting large pharma, but small biotechs and generics makers could face a credit crunch.
-
Permission granted by SaNOtize/Gilly Regev
ProfileFrom vineyards to antivirals, Gilly Regev brings creative thinking to science
The CEO of SaNOtize is tapping into outside-the-box innovation to develop a nitric oxide-delivery platform to treat and prevent COVID-19.
-
Stock via Getty Images
4 tips for landing your next C-suite role in pharma
Even execs get the blues — and when they’re ready for a fresh start, Leslie Loveless, CEO of Slone Partners, says these dos and don’ts could make or break their next job move.
-
Permission granted by Dan Vahdat.
Q&A'Nobel Prize of pharma' helps put Huma's digital health platform on the global map
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
-
Karissa Waddick/PharmaVoice
#DIA2022: Building 'guardrails' in the FDA's accelerated approval program
Regulatory experts weigh in on ways to enhance the controversial drug approval approach.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Kronos Bio's Barbara Kosacz
Deal-maker, mentor and biotech industry mover and shaker, the COO and general counsel brings her 'smiling tiger' skills to her new role at the emerging company.
-
Michael Gibney/PharmaVoice
#DIA2022: How the industry's top regulator views the future of healthcare
In the evolution of healthcare, data is the linchpin to making drug development more efficient.
-
Valiantsin Suprunovich via Getty Images
The public health sleuth
In her decades-long career, Mary Pittman, CEO of the Public Health Institute, has seen — and helped solve — one public health mystery after another.
-
Stock via Getty Images
Q&ABiotech spotlight: Karuna Therapeutics' mission to rejuvenate the field of neuroscience
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
-
ChiccoDodiFC via Getty Images
A patient-funded ALS drug offers hope where few treatments exist
Eledon Pharmaceuticals’ grassroots-backed drug recently entered clinical trials.
-
Drew Angerer / Staff via Getty Images
TikTok tutorial: How pharma can embrace the video platform's educational potential
Ogilvy Health’s director of social strategy, Katie Ferrigno, busts myths and provides tips on how biopharmas can take advantage of TikTok’s unique features to connect with patients.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Tango Therapeutics' Dr. Barbara Weber
A pioneer in genetic medicine, Dr. Barbara Weber continues to push the envelope to expand the reach of therapies based on genetic targeting.
-
Michael Ciaglo / Stringer via Getty Images
ProfileBuoyed by COVID-19 shot, J&J's vaccines head sees a new golden age approaching
Janssen’s goal to have ‘a vaccine for the world’ is part of what drew Penny Heaton to the company and its work.
-
iStock via Getty Images
Q&AWhy biomanufacturing is the next innovation frontier for genomic therapies
While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.
-
Permission granted by Editas/Gilmore O'Neill
Q&AFirst 90 Days: Editas Medicine's Gilmore O'Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
-
iStock via Getty Images
Making moves: Civica, Astellas, Inozyme and more announce key new hires
The latest hiring moves from Civica, Astella, Inozyme and the Flagship Pioneering-founded Tessera Therapeutics.
-
Stock via Getty Images
Q&AA combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
-
Permission granted by Merck/Adrelia Allen
As cancer innovations thrive, patient access is the next piece of the puzzle
Why enhanced clinical trials and diagnostics are keys to boosting patient access to cancer care.
-
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Janssen's Najat Khan
Janssen’s Najat Khan, Ph.D., chief data science officer and global head of strategy and operations, shares how the company is using next-gen tech to ‘reimagine’ medicine.
-
Jonathan Ross via Getty Images
Pharma giants take on Appalachian cancer rates in newest screening initiative
AstraZeneca and Bristol Myers Squibb are teaming up with the nonprofit Association of Community Cancer Centers to increase lung cancer screening in rural Appalachia for the long haul.
-
Stock via Getty Images
ProfileAfter losing her daughter to a rare disease, Sharon King is looking to rewrite the playbook of drug development
The communications pro is lending her community-building, storytelling expertise to the Bespoke Gene Therapy Consortium.
-
Permission granted by Merck/Eric Rubin
How to build a cancer pipeline: Big Pharma oncology heads on driving science forward
Executives leading the cancer departments at J&J, Merck and Takeda chime in on what it takes to construct a successful and sustainable oncology drug pipeline.
-
Permission granted by David Jimenez.
Q&AFirst 90 Days: Janssen Immunology's David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
-
iStock via Getty Images
Aduhelm's Medicare woes leave questions about lofty premiums
A single drug’s effect on the premiums that Medicare beneficiaries pay is raising questions about how these levels are set and what factors play a part.
-
Permission granted by Flagship Pioneering/Avak Kahvejian.
ProfileFlagship's creative approach to finding the next big idea in biopharma
Avak Kahvejian, partner at Flagship Pioneering, a company that conceives, creates and launches bioplatform companies like Moderna, discusses its latest venture, ProFound Therapeutics.
